Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AccuHist DM is a multi-ingredient over-the-counter (OTC) combination medication used for the symptomatic relief of the common cold, influenza, allergies, and other respiratory conditions such as sinusitis and bronchitis. It contains four active small molecule components: brompheniramine maleate (an antihistamine), dextromethorphan hydrobromide (a cough suppressant), pseudoephedrine hydrochloride (a nasal decongestant), and guaifenesin (an expectorant). Brompheniramine acts as a competitive H1 receptor antagonist to alleviate allergic symptoms like sneezing and runny nose. Dextromethorphan acts centrally on the cough center in the medulla to elevate the cough threshold. Pseudoephedrine is a sympathomimetic amine that stimulates alpha-adrenergic receptors in the nasal mucosa to produce vasoconstriction and reduce swelling. Guaifenesin increases the volume and reduces the viscosity of respiratory tract secretions, facilitating their removal. The product is primarily formulated for pediatric use as oral drops or syrup.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AccuHist DM.